April 2026 - Pharmaceutical Market Europe

April 2026 - Pharmaceutical Market Europe
Published on 23 April 2026

Description:

Explore the April issue of PME, featuring the $150bn GLP-1 weight loss market and the race for oral obesity medications. This edition covers critical challenges in tuberculosis treatment adherence and the groundbreaking use of CAR-T cell therapies for lupus, an autoimmune condition disproportionately affecting women and ethnic minority groups. Stay ahead with the latest in pharmaceutical innovation and clinical breakthroughs.

Preview:

32 articles from this collection:
PME April 2026
PME April 2026
2 COMMUNIQUE Awards
2 COMMUNIQUE Awards
3 Comment
3 Comment
4 - PME Advert
4 - PME Advert
5 Contents
5 Contents
6 News
6 News
Roche and Ascidian agree to $1.8bn neurological disease partnership
7 News
7 News
8 News
8 News
Researchers identify new major cause of inflammatory bowel disease
9 News
9 News
10 DERMATOLOGY NEWS
10 DERMATOLOGY NEWS
11 DERMATOLOGY NEWS
11 DERMATOLOGY NEWS
12 Brian D Smith Darwin’s Medicine - THE HUBS AND THE SPOKES
12 Brian D Smith Darwin’s Medicine - THE HUBS AND THE SPOKES
How much time do you spend thinking about the impact of what is working and what is not in today’s organisational reality, versus what was captured in the situational analysis in your brand plan?
13 Mike Dixon PARTNERSHIP HEALTH
13 Mike Dixon PARTNERSHIP HEALTH
14 INTEGRATED INSIGHTS AND THE CHANGING IMPERATIVE FOR PHARMA LEADERS
14 INTEGRATED INSIGHTS AND THE CHANGING IMPERATIVE FOR PHARMA LEADERS
15 WHEN INNOVATION ISN’T ENOUGH: VACCINE COMMUNICATION MATTERS
15 WHEN INNOVATION ISN’T ENOUGH: VACCINE COMMUNICATION MATTERS
16-17 TB – the search for a cure
16-17 TB – the search for a cure
Across almost every sector, brands are multiplying their investment in creativity
18-19 The challenges of finding a cure for lupus and related autoimmune conditions
18-19 The challenges of finding a cure for lupus and related autoimmune conditions
CAR-Ts pose a unique challenge for healthcare systems, exacerbated by uncertainty around their long-term, real-world value
20 - Lab News
20 - Lab News
21 THOUGHT LEADER Hamell
21 THOUGHT LEADER Hamell
22-25 Leading through platforms
22-25 Leading through platforms
26 THOUGHT LEADER Syneos
26 THOUGHT LEADER Syneos
27 MARKETING & COMMS
27 MARKETING & COMMS
28-29 Creating a bridge between weight loss drugs and long-term behaviour change
28-29 Creating a bridge between weight loss drugs and long-term behaviour change
30 ETHICAL SOCIAL MEDIA USE
30 ETHICAL SOCIAL MEDIA USE
31 THOUGHT LEADER Veeva
31 THOUGHT LEADER Veeva
Picking your omnichannel direction requires a disciplined, scientific approach
32-33 AI AND CLINICAL TRIALS
32-33 AI AND CLINICAL TRIALS
34-35 Europe’s next health innovation engine
34-35 Europe’s next health innovation engine
36 Appointments
36 Appointments
37 Appointments
37 Appointments
38 Appointments
38 Appointments
39 PMPS
39 PMPS
40 FlyPharma
40 FlyPharma